Global Information
회사소개 | 문의 | 비교리스트

시신경염 : 파이프라인 리뷰

Optic Neuritis - Pipeline Review, H1 2020

리서치사 Global Markets Direct
발행일 2020년 04월 상품 코드 251578
페이지 정보 영문 48 Pages
가격
US $ 2,000 ₩ 2,396,000 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,792,000 PDF by E-mail (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 7,189,000 PDF by E-mail (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


시신경염 : 파이프라인 리뷰 Optic Neuritis - Pipeline Review, H1 2020
발행일 : 2020년 04월 페이지 정보 : 영문 48 Pages

시신경은 눈으로부터 뇌에 시각 정보를 전달하는 신경 섬유다발로 이것들이 염증을 일으킨 것이 시신경염이며, 통증, 실명, 섬광 등이 나타납니다. 위험인자로 노화, 유전 변이, 성별 등이 있습니다.

시신경염(Optic Neuritis) 치료제 개발 파이프라인 현황과 최신 업데이트에 의한 각 개발 단계 비교 분석, 기업과 연구기관에 의해서 개발중인 치료제, 치료제 평가, 최신 뉴스와 발표, 후기 단계 및 중지된 프로젝트에 관한 정보 등을 전해드립니다.

서론

  • 조사 범위

시신경염 개요

치료제 개발

  • 파이프라인 제품;개요
  • 기업별 파이프라인 제품
  • 대학/연구기관별 파이프라인 제품
  • 기업에서 개발중인 제품
  • 대학/연구기관에서 개발중인 제품

치료제 평가

  • 표적별
  • 작용기전별
  • 투여 경로별
  • 분자 종류별

치료제 개발 참여 기업

  • 2-BBB Medicines BV
  • Biogen Inc
  • Bionure Farma SL
  • Commence Bio Inc
  • Lipocure Ltd
  • Meta-IQ ApS
  • Neuralstem Inc
  • Teijin Limited 파마

약제 개요

휴지중인 프로젝트

개발이 중지된 제품

제품 개발 마일스톤

  • 주요 뉴스와 프레스 릴리스

부록

도표

LSH 17.06.12

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

List of Tables

  • Number of Products under Development for Optic Neuritis, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Optic Neuritis - Pipeline by Bionure Farma SL, H1 2020
  • Optic Neuritis - Pipeline by Commence Bio Inc, H1 2020
  • Optic Neuritis - Pipeline by EnhanX Biopharm Inc, H1 2020
  • Optic Neuritis - Pipeline by Japan Innovative Therapeutics Inc, H1 2020
  • Optic Neuritis - Pipeline by Meta-IQ ApS, H1 2020
  • Optic Neuritis - Pipeline by Mitochon Pharmaceuticals Inc, H1 2020
  • Optic Neuritis - Pipeline by Noveome Biotherapeutics Inc, H1 2020
  • Optic Neuritis - Pipeline by SanBio Inc, H1 2020
  • Optic Neuritis - Dormant Projects, H1 2020
  • Optic Neuritis - Discontinued Products, H1 2020

List of Figures

  • Number of Products under Development for Optic Neuritis, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products by Targets, H1 2020
  • Number of Products by Stage and Targets, H1 2020
  • Number of Products by Mechanism of Actions, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Optic Neuritis - Pipeline Review, H1 2020, provides an overview of the Optic Neuritis (Ophthalmology) pipeline landscape.

Optic neuritis is an inflammation of the optic nerve, the bundle of nerve fibers that transmits visual information from eye to brain. Symptoms include pain, vision loss, dyschromatopsia, Uhthoff's phenomenon and flashing lights. Risk factors include age and genetic mutations.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Optic Neuritis - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Optic Neuritis (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Optic Neuritis (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Optic Neuritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I and Preclinical stages are 4 and 5 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.

Optic Neuritis (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Optic Neuritis (Ophthalmology).
  • The pipeline guide reviews pipeline therapeutics for Optic Neuritis (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Optic Neuritis (Ophthalmology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Optic Neuritis (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Optic Neuritis (Ophthalmology)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Optic Neuritis (Ophthalmology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Optic Neuritis (Ophthalmology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Optic Neuritis - Overview
    • Optic Neuritis - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Optic Neuritis - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Optic Neuritis - Companies Involved in Therapeutics Development
    • Bionure Farma SL
    • Commence Bio Inc
    • EnhanX Biopharm Inc
    • Japan Innovative Therapeutics Inc
    • Meta-IQ ApS
    • Mitochon Pharmaceuticals Inc
    • Noveome Biotherapeutics Inc
    • SanBio Inc
  • Optic Neuritis - Drug Profiles
    • BN-201 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CMB-200 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ENX-201 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • etomoxir - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • gypenoside - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MP-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MP-201 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule for Optic Neuritis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ST-266 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Stem Cell Therapy for Optic Neuritis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Optic Neuritis - Dormant Projects
  • Optic Neuritis - Discontinued Products
  • Optic Neuritis - Product Development Milestones
    • Featured News & Press Releases
      • May 15, 2019: Bionure appoints Dr. Lucia Septien as chief medical officer
      • May 09, 2019: Noveome Biotherapeutics announces publication of further preclinical results supporting the neuroprotective properties of ST266 in retinal ganglion cells
      • May 07, 2019: Neuroprotection Biotech Bionure Reports Successful Phase 1 Study for Lead Candidate BN201
      • Oct 09, 2018: Bionure appoints Dr. Laurent Nguyen as CEO
      • May 16, 2018: Bionure initiates a Phase 1 clinical trial of its lead compound BN201 in the United Kingdom
      • Jan 31, 2017: Noveome Biotherapeutics Publishes Data Demonstrating Anti-inflammatory Activity of ST266 in a Preclinical Model of Optic Neuritis
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer
Back to Top
전화 문의
F A Q